Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC.

Beizaei, Kaweh

Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. [electronic resource] - Head & neck 01 2019 - 208-215 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1097-0347

10.1002/hed.25440 doi


Carcinoma, Squamous Cell--drug therapy
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Crizotinib--pharmacology
ErbB Receptors--antagonists & inhibitors
Head and Neck Neoplasms--drug therapy
Humans
Indoles--pharmacology
Phosphorylation--drug effects
Piperazines--pharmacology
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins c-met--antagonists & inhibitors
Sorafenib--pharmacology
Sulfonamides--pharmacology